New drug for Medullary Thyroid Cancer licensed

April 9th, 2012

In February 2012 Astra Zeneca received approval from the European Medicines Agency for Calpresa (Vandetanib), the first and only tyrosine kinase inhibitor licensed for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

The approval of Calpresa was based of the results of the ZETA Study, a placebo controlled clinical study of 331 patients with advanced MTC.

If you have advanced MTC, ask your Thyroid Cancer Care Team about Calpresa.

Leave a Reply

Your email address will not be published. Required fields are marked *

We are available on this number on Tuesdays and Fridays from 10 am to 4 pm. Outside these times, please leave a message on our answer phone and we will get back to you as soon as we can.